Market Closed -
Nasdaq
04:00:00 2024-06-13 pm EDT
5-day change
1st Jan Change
287.6
USD
+2.03%
+4.05%
+30.79%
This article is reserved for members
Not a member ?
Free registration
Transcript : United Therapeutics Corporation Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-12-2024 04:00 PM
Jun. 12
Wells Fargo Raises Price Target on United Therapeutics to $350 From $325, Maintains Overweight Rating
Jun. 12
MT
Liquidia's Yutrepia Launch Cleared as Court Denies Injunction
Jun. 03
MT
United Therapeutics Insider Sold Shares Worth $545,800, According to a Recent SEC Filing
May. 16
MT
United Therapeutics Insider Sold Shares Worth $1,911,532, According to a Recent SEC Filing
May. 14
MT
United Therapeutics Insider Sold Shares Worth $1,898,393, According to a Recent SEC Filing
May. 10
MT
United Therapeutics Insider Sold Shares Worth $949,737, According to a Recent SEC Filing
May. 08
MT
United Therapeutics Insider Sold Shares Worth $1,871,233, According to a Recent SEC Filing
May. 07
MT
United Therapeutics Insider Sold Shares Worth $2,585,601, According to a Recent SEC Filing
May. 06
MT
United Therapeutics Insider Sold Shares Worth $582,195, According to a Recent SEC Filing
May. 06
MT
United Therapeutics Insider Sold Shares Worth $1,829,903, According to a Recent SEC Filing
May. 03
MT
UBS Adjusts Price Target on United Therapeutics to $300 From $290, Maintains Buy Rating
May. 02
MT
Oppenheimer Adjusts United Therapeutics Price Target to $400 From $375, Maintains Outperform Rating
May. 02
MT
Transcript : United Therapeutics Corporation, Q1 2024 Earnings Call, May 01, 2024
May. 01
United Therapeutics Q1 Net Income, Revenue Advance; Shares Rise Pre-Bell
May. 01
MT
Earnings Flash (UTHR) UNITED THERAPEUTICS CORPORATION Reports Q1 Revenue $677.7M, vs. Street Est of $624.2M
May. 01
MT
Tranche Update on United Therapeutics Corporation's Equity Buyback Plan announced on March 25, 2024.
May. 01
CI
United Therapeutics Corporation Reports Earnings Results for the First Quarter Ended March 31, 2024
May. 01
CI
United Therapeutics Insider Sold Shares Worth $1,704,174, According to a Recent SEC Filing
Apr. 23
MT
United Therapeutics Q1 Results Could Fall Short of Market Expectations, Oppenheimer Says
Apr. 23
MT
United Therapeutics Insider Sold Shares Worth $1,704,990, According to a Recent SEC Filing
Apr. 19
MT
United Therapeutics Insider Sold Shares Worth $1,682,819, According to a Recent SEC Filing
Apr. 17
MT
United Therapeutics Insider Sold Shares Worth $1,707,775, According to a Recent SEC Filing
Apr. 15
MT
United Therapeutics Insider Sold Shares Worth $6,831,737, According to a Recent SEC Filing
Apr. 11
MT
United Therapeutics Insider Sold Shares Worth $4,727,736, According to a Recent SEC Filing
Apr. 09
MT
Duration Auto. 2 months 3 months 6 months 9 months 1 year 2 years 5 years 10 years Max.
Period Day Week
More charts
United Therapeutics Corporation is a pharmaceutical company. It markets and sells commercial therapies to treat pulmonary arterial hypertension (PAH): Tyvaso DPI (treprostinil) Inhalation Powder (Tyvaso DPI); Tyvaso (treprostinil) Inhalation Solution (nebulized Tyvaso), which includes the Tyvaso Inhalation System; Remodulin (treprostinil) Injection (Remodulin); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca). Tyvaso DPI and nebulized Tyvaso are also approved to treat pulmonary hypertension associated with interstitial lung disease (PH-ILD). It also markets and sells an oncology product, Unituxin (dinutuximab) Injection (Unituxin) for treatment of high-risk neuroblastoma, and the Remunity Pump for Remodulin (Remunity). Tyvaso DPI is a drug-device combination product that incorporates the dry powder formulation technology and Dreamboat inhalation device technology used in MannKindâs Afrezza (insulin human) Inhalation Powder.
More about the company
Last Close Price
287.6
USD
Average target price
295.9
USD
Spread / Average Target
+2.91%
Consensus
1st Jan change
Capi.
+30.79% 12.76B +46.03% 55.66B -7.53% 38.98B +35.88% 38.8B -9.38% 27.32B +12.31% 26.29B -16.38% 20.25B +28.57% 12.18B -0.36% 12.12B -10.14% 10.94B
Other Biotechnology & Medical Research
+951% of historical performance
More than 20 years at your side
Our Experts are here for you
OUR EXPERTS ARE HERE FOR YOU
Monday - Friday 9am-12pm / 2pm-6pm GMT + 1